title: Clinical efficacy of arbekacin for Gram-negative bacteria.
abstract: In an analysis of methicillin-resistant Staphylococcus aureus (MRSA) infected patients treated with arbekacin (ABK) only, Gram-negative bacteria (GNB) that were inhibited by low minimal inhibitory concentrations (MICs) of amikacin (AMK) or gentamycin (GM) were eradicated by the end of the ABK treatment. On the other hand, GNB that were only inhibited by high MICs of AMK or GM persisted until the end of treatment with ABK only. Thus, ABK can be expected to be effective even in cases of mixed infection with GNB and MRSA.
authors.affiliation: Department of Pharmacy, Kitasato East University Hospital, 2-1-1, Asamizodai, Minami-ku, Sagamihara, Kanagawa 252-0380, Japan. yuki@kitasato-u.ac.jp
authors.forename: Yukihiro
authors.initials: Y
authors.lastname: Hamada
authors.forename: Kazuyoshi
authors.initials: K
authors.lastname: Tamura
authors.forename: Ikumi
authors.initials: I
authors.lastname: Koyama
authors.forename: Masakazu
authors.initials: M
authors.lastname: Kuroyama
authors.forename: Kazuo
authors.initials: K
authors.lastname: Yago
authors.forename: Keisuke
authors.initials: K
authors.lastname: Sunakawa
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D060085:Coinfection / Q000188:drug therapy / Q000382:microbiology*; D003982:Dibekacin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006090:Gram-Negative Bacteria / Q000187:drug effects* / Q000302:isolation & purification; D016905:Gram-Negative Bacterial Infections / Q000188:drug therapy / Q000382:microbiology*; D006801:Humans; D008297:Male; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D013203:Staphylococcal Infections / Q000188:drug therapy / Q000382:microbiology*
chemical_list: D000900:Anti-Bacterial Agents; D003982:Dibekacin; C031986:arbekacin